[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  MarketMaestro [@MarketMaestro1](/creator/twitter/MarketMaestro1) on x 27.6K followers Created: 2025-07-24 15:56:22 UTC $SGMT Sagimet Biosciences (NASDAQ:SGMT) traded higher on Thursday after Canaccord Genuity launched its coverage with a Buy recommendation, citing the potential of its lead asset denifanstat, targeted at a liver disease called metabolic dysfunction-associated steatohepatitis (MASH). With a 12-month price target of $28, Canaccord analyst Edward Nash argued that the California-based biotech stands out from its peers in the MASH space, given its combination approach against the fatty liver disease. “Sagimet is one of the more compelling names in the MASH space given their lead drug denifanstat’s differentiated mechanism of action,” Nash wrote, adding that the combo tying SGMT’s FASN inhibitor with the THR-ß agonist resmetirom could reach the market in 2034, leading to $1.7B in sales in 2035. Sagimet (NASDAQ:SGMT), the only company with an FASN inhibitor in clinical development for MASH, has also launched a Phase I trial for TVB-3567, its second FASN inhibitor for which its Chinese partner, Ascletis, has posted positive Phase X data for acne. While TVB-3567 is set to enter mid-stage development in 2026, and Nash hasn’t included TVB-3567 in his model, he argued that with ~50M Americans affected by acne and 5M seeking treatment, the skin condition “offers blockbuster potential for an effective oral treatment.”  XXXXX engagements  **Related Topics** [$sgmt](/topic/$sgmt) [Post Link](https://x.com/MarketMaestro1/status/1948411948812358060)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
MarketMaestro @MarketMaestro1 on x 27.6K followers
Created: 2025-07-24 15:56:22 UTC
$SGMT Sagimet Biosciences (NASDAQ:SGMT) traded higher on Thursday after Canaccord Genuity launched its coverage with a Buy recommendation, citing the potential of its lead asset denifanstat, targeted at a liver disease called metabolic dysfunction-associated steatohepatitis (MASH).
With a 12-month price target of $28, Canaccord analyst Edward Nash argued that the California-based biotech stands out from its peers in the MASH space, given its combination approach against the fatty liver disease.
“Sagimet is one of the more compelling names in the MASH space given their lead drug denifanstat’s differentiated mechanism of action,” Nash wrote, adding that the combo tying SGMT’s FASN inhibitor with the THR-ß agonist resmetirom could reach the market in 2034, leading to $1.7B in sales in 2035.
Sagimet (NASDAQ:SGMT), the only company with an FASN inhibitor in clinical development for MASH, has also launched a Phase I trial for TVB-3567, its second FASN inhibitor for which its Chinese partner, Ascletis, has posted positive Phase X data for acne.
While TVB-3567 is set to enter mid-stage development in 2026, and Nash hasn’t included TVB-3567 in his model, he argued that with ~50M Americans affected by acne and 5M seeking treatment, the skin condition “offers blockbuster potential for an effective oral treatment.”
XXXXX engagements
Related Topics $sgmt